Business Context and Reporting Period
This Form 8-K Current Report was filed by Second Sight Medical Products, Inc. (Note: The request metadata referenced "Vivani Medical, Inc.", but the filing text identifies the registrant as Second Sight Medical Products, Inc.) on June 22, 2021, with the event closing on June 25, 2021. The report details the entry into a material definitive agreement for a firm commitment underwritten public offering of common stock.
Key Financial Metrics
- Offering Size: 10,000,000 shares of common stock plus an over-allotment option for up to 1,500,000 additional shares.
- Offering Price: $5.00 per share.
- Total Shares Sold: 11,500,000 shares (including full exercise of the over-allotment option).
- Gross Proceeds: Approximately $57.5 million.
- Underwriting Discounts and Commissions: 7.0% of gross cash proceeds.
- Other Offering Expenses: Approximately $125,000 (excluding underwriting discounts).
- Use of Proceeds: Primarily for the development of the Orion technology and general corporate purposes.
Material Changes
The filing reports a significant capital raise event. The company successfully closed the offering on June 25, 2021, raising $57.5 million in gross proceeds. This represents a material increase in the company's liquidity position compared to the period prior to the offering. The filing does not provide comparative financial metrics (revenue, profit, or cash flow) for prior periods as this is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
- Management Commentary: The company intends to utilize net proceeds to advance the development of its Orion device.
- Lock-Up Agreements: Executive officers, directors, and shareholders owning 5% or more of the company have entered into 30-day lock-up agreements restricting the sale or transfer of their shares.
- Risks and Uncertainties: The report contains forward-looking statements regarding expected net proceeds. It references various risks detailed in other SEC filings, noting that actual results may differ due to uncertainties.
- Unusual Items: None reported beyond the standard terms of the underwriting agreement and the capital raise itself.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7.0% underwriting discount and $125,000 in other expenses.
- Confirm the specific timeline and milestones for the "Orion technology" development funded by these proceeds.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific representations, warranties, and termination provisions.
- Check the status of the 30-day lock-up period expiration for major shareholders.
- Review the company's most recent 10-K or 10-Q for baseline financial health (revenue, cash on hand) prior to this capital injection.